Japenese pharmaceutical company Takeda may buy its Swiss rival Nycomed, the European Commission said on 2 August.
The Commission says it has cleared the merger because the combined market of Takeda and Nycomed in Austria, Germany and Italy, is not very high, so the merger would not impede competition significantly.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.